AVI-4015 is under clinical development by Avixgen and currently in Phase I for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase I drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVI-4015’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVI-4015 is under development for the treatment of keratoconjunctivitis sicca (dry eye). It is administered through ophthalmic route in the form of eye drops. The drug candidate is a repositioning drug acts by targeting DDR1 receptor and is developed based on advanced cell-penetrating peptide (ACP), that delivers the therapeutic drug.
Avixgen is a Pharmaceuticals and Healthcare company that offers health care services like therapies and medications for virus infections. The company is Headquartered in Gwanak-gu, Seoul, Republic of Korea (South Korea).
For a complete picture of AVI-4015’s drug-specific PTSR and LoA scores, buy the report here.